Clinical Value of Human c-Met Gene Amplification Detection in Precision Therapy for Solid Tumors

c-Met Gene Amplification and Tumor Correlation

The c-Met gene encodes the hepatocyte growth factor receptor, which is involved in cell proliferation, migration, and angiogenesis. Gene amplification leads to receptor overexpression or persistent activation and has been confirmed to be associated with the development and progression of various solid tumors, including non-small cell lung cancer, gastric cancer, and colorectal cancer. The Human c-Met Gene Amplification Detection Kit (Fluorescence In Situ Hybridization Method) provides important molecular stratification evidence for clinical practice by directly observing changes in gene copy number in tumor tissues.

Application in Non-Small Cell Lung Cancer

In non-small cell lung cancer (NSCLC), c-Met amplification is one of the important mechanisms of resistance to EGFR-targeted therapy. Multiple studies suggest that c-Met amplification detection results can assist in determining the cause of resistance to EGFR-TKIs and guide subsequent treatment selection. For example, some NSCLC patients harboring c-Met amplification may benefit from a combination regimen of c-Met inhibitors and EGFR-TKIs. During detection, attention should be paid to distinguishing signal increases caused by polyploidy from true amplification, and centromeric probes are generally required for correction.

Application in Gastric Cancer and Other Solid Tumors

In gastric cancer, the incidence of c-Met amplification is approximately 2%–4% and is associated with poor prognosis. Targeted drugs against c-Met (such as crizotinib, capmatinib, etc.) have shown efficacy in clinical trials. The Human c-Met Gene Amplification Detection Kit (Fluorescence In Situ Hybridization Method) can be used to screen suitable patients. For solid tumors such as hepatocellular carcinoma and head and neck squamous cell carcinoma, although the frequency of c-Met amplification is relatively low, detection still has potential clinical value. It is worth noting that detection results should be comprehensively evaluated in combination with other biomarkers (such as MET protein expression and gene mutations).

Advantages and Limitations of the Detection Kit

Compared with other methods (such as NGS and IHC), fluorescence in situ hybridization has advantages including being intuitive, preserving tissue morphology, and having relatively controllable costs. However, it also has limitations such as strong subjectivity in interpretation, relatively low throughput, and high technical requirements for operators. At present, many kits have achieved standardized interpretation software assistance, which can improve consistency. In clinical application, it should be noted that interpretation standards may differ among laboratories, and it is recommended to use the same kit and follow unified interpretation thresholds.

Outlook

With the advancement of precision medicine, the Human c-Met Gene Amplification Detection Kit (Fluorescence In Situ Hybridization Method) is playing an increasingly important role in companion diagnostics. In the future, multi-gene panel combined detection, artificial intelligence-assisted interpretation, and the supplementation of liquid biopsy methods will further improve the c-Met status assessment system. Version updates and performance improvements of the kit will also help improve detection sensitivity and specificity.